The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Naproxen Sodium and Diphenhydramine HCL
Naproxen Sodium and Diphenhydramine HCL · DIPHENHYDRAMINE HYDROCHLORIDE 25 mg/1; NAPROXEN SODIUM 220 mg/1 · Tablet · Oral · Target Corporation
NDC 11673-0819-08 · 80 TABLET in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- ANDA213663
- TE code
- —
- Approval date
- Sep 24, 2020
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Naproxen Sodium and Diphenhydramine HCL (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Target Corporation | DIPHENHYDRAMINE HYDROCHLORIDE 25 mg/1; NAPROXEN SODIUM 220 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Naproxen Sodium and Diphenhydramine HCL — NDC 11673-0819-08," retrieved September 3, 2026, https://drugdashboards.com/drug/11673081908.
Free to cite with attribution — see how the data is put together.